dc.creator | Kotsiou O.S., Zarogiannis S.G., Gourgoulianis K.I. | en |
dc.date.accessioned | 2023-01-31T08:44:59Z | |
dc.date.available | 2023-01-31T08:44:59Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1016/j.rmed.2016.12.005 | |
dc.identifier.issn | 09546111 | |
dc.identifier.uri | http://hdl.handle.net/11615/75240 | |
dc.description.abstract | Objective Nonsteroidal anti-inflammatory drug (NSAID) pre-hospitalization consumption might affect the course of pneumonia. We opted to assess the potential effects of pre-hospitalization use of NSAIDs in patients with pleuropulmonary infection in the context of the duration of hospitalization. Methods A prospective observational study of 57 consecutive patients with a diagnosis of pneumonia and parapneumonic pleural effusion was conducted. The exact medication history the previous fifteen days was recorded. Results Prehospital use of NSAIDs >6 days was positively associated with prolonged hospitalization extending out for approximately 10 days. Immunosuppression was an independent risk factor for prolonged hospitalization of more than 5 days. This group of patients also had more complicated pleural effusions and difficult to treat management. In the immunocompetent group of patients, there was a negative inverse correlation of duration of NSAIDs use with pleural fluid pH and glucose. The longer medication with NSAIDs correlated with lower values of C–reactive protein, and erythrocyte sedimentation rate. Importantly, the early prehospital antibiotic use significantly prevented the development of empyema. Conclusion Our findings highlight the potential complications involved with prehospital use of NSAIDs and especially that prolonged NSAID use which may lead to longer hospitalization duration and more complicated pleural effusions. © 2016 Elsevier Ltd | en |
dc.language.iso | en | en |
dc.source | Respiratory Medicine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006241143&doi=10.1016%2fj.rmed.2016.12.005&partnerID=40&md5=a45cb165a12d05dd4c652ae161754044 | |
dc.subject | antibiotic agent | en |
dc.subject | C reactive protein | en |
dc.subject | glucose | en |
dc.subject | nonsteroid antiinflammatory agent | en |
dc.subject | antiinfective agent | en |
dc.subject | nonsteroid antiinflammatory agent | en |
dc.subject | adult | en |
dc.subject | alcoholism | en |
dc.subject | antibiotic therapy | en |
dc.subject | Article | en |
dc.subject | community acquired pneumonia | en |
dc.subject | coughing | en |
dc.subject | drug use | en |
dc.subject | early intervention | en |
dc.subject | emergency care | en |
dc.subject | empyema | en |
dc.subject | erythrocyte sedimentation rate | en |
dc.subject | female | en |
dc.subject | hospital admission | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | immune deficiency | en |
dc.subject | immunocompetence | en |
dc.subject | immunocompromised patient | en |
dc.subject | length of stay | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | malignant neoplastic disease | en |
dc.subject | medical history | en |
dc.subject | middle aged | en |
dc.subject | neuromuscular disease | en |
dc.subject | neutrophil | en |
dc.subject | observational study | en |
dc.subject | pH | en |
dc.subject | pleura effusion | en |
dc.subject | pneumonia | en |
dc.subject | priority journal | en |
dc.subject | prospective study | en |
dc.subject | smoking | en |
dc.subject | Streptococcus pneumonia | en |
dc.subject | thoracocentesis | en |
dc.subject | thorax drainage | en |
dc.subject | thorax pain | en |
dc.subject | treatment duration | en |
dc.subject | aged | en |
dc.subject | community acquired infection | en |
dc.subject | drug administration | en |
dc.subject | drug utilization | en |
dc.subject | hospitalization | en |
dc.subject | immunology | en |
dc.subject | microbiology | en |
dc.subject | pleura | en |
dc.subject | pleura effusion | en |
dc.subject | pneumonia | en |
dc.subject | respiratory tract infection | en |
dc.subject | statistics and numerical data | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Anti-Bacterial Agents | en |
dc.subject | Anti-Inflammatory Agents, Non-Steroidal | en |
dc.subject | Community-Acquired Infections | en |
dc.subject | Drug Administration Schedule | en |
dc.subject | Drug Utilization | en |
dc.subject | Female | en |
dc.subject | Hospitalization | en |
dc.subject | Humans | en |
dc.subject | Immunocompromised Host | en |
dc.subject | Length of Stay | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Pleura | en |
dc.subject | Pleural Effusion | en |
dc.subject | Pneumonia | en |
dc.subject | Prospective Studies | en |
dc.subject | Respiratory Tract Infections | en |
dc.subject | W.B. Saunders Ltd | en |
dc.title | Prehospital NSAIDs use prolong hospitalization in patients with pleuro-pulmonary infection | en |
dc.type | journalArticle | en |